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ABSTRACT
Although urgently needed in clinical practice, a cardioprotective therapeutic approach against myocardial ischemia/
reperfusion injury remains to be established. Remote ischemic preconditioning (rIPC) and ischemic preconditioning 
(IPC) represent promising tools comprising three entities: the generation of a protective signal, the transfer of the signal 
to the target organ, and the response to the transferred signal resulting in cardioprotection. However, in light of recent 
scientific advances, many controversies arise regarding the efficacy of the underlying signaling. We here show methods 
for the generation of the signaling cascade by rIPC as well as IPC in a mouse model for in vivo myocardial ischemia/
reperfusion injury using highly reproducible approaches. This is accomplished by taking advantage of easily applicable 
preconditioning strategies compatible with the clinical setting. We describe methods for using laser Doppler perfusion 
imaging to monitor the cessation and recovery of perfusion in real time. The effects of preconditioning on cardiac function 
can also be assessed using ultrasound or magnetic resonance imaging approaches. On a cellular level, we confirm how 
tissue injury can be monitored using histological assessment of infarct size in conjunction with immunohistochemistry to 
assess both aspects in a single specimen. Finally, we outline, how the rIPC-associated signaling can be transferred to the 
target cell via conservation of the signal in the humoral (blood) compartment. This compilation of experimental protocols 
including a conditioning regimen comparable to the clinical setting should proof useful to both beginners and experts in 
the field of myocardial infarction, supplying information for the detailed procedures as well as troubleshooting guides.
Keywords: remote ischemic preconditiong, myocardial ischemia/reperfusion, plasma transfer, laser Doppler perfusion 
imaging, magnetic resonance imaging
BACKGROUND
With 17.5 million (3 out of every 10 deaths) disease-related victims 
in 2012, ischemic heart disease and particularly acute myocardial in-
farction constitutes the leading cause of death worldwide. Prototypical 
myocardial infarction occurs as a result of arteriosclerotic plaque rupture 
and thrombus formation [1]. Occlusion of the corresponding coronary 
artery causes a cessation of blood, in particular oxygen (O2) supply to 
the area at risk (AAR). The treatment of choice is the restoration of 
vessel patency. A timely reperfusion regimen, preferably by coronary 
intervention, is the recommended therapy but the rapid restoration 
of blood and particularly O2 supply imposes additional reperfusion 
injury upon the heart with no current treatment available. Experiments 
targeting the mediators of this so-called ischemia/reperfusion (I/R) 
injury have provided novel therapeutic approaches. However, none of 
these strategies have yet been successfully implemented into clinical 
practice. The robust cardioprotective effect of ischemic conditioning, 
as documented in animal models, certainly warrants more innovative 
investigations both at the experimental and clinical levels [2,3].
The term ‘ischemic conditioning’ refers to the priming of the tissue 
at risk with short non-deleterious and repetitive phases of sublethal 
ischemia [4]. In the scope of myocardial I/R, this renders the cardio-
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myocyte capable of protecting itself. The ischemic conditioning stim-
ulus can be effectively applied before, during or after the index (main) 
ischemia (pre-, per-, postconditioning, Fig. 1) [4-9]. Interestingly, the 
ischemic stimulus does not need necessarily to be applied to the index 
organ, but can also be executed at a remote site, e.g., the arm (Fig. 1). 
Conceptually, three components of remote ischemic preconditioning 
(rIPC) can be distinguished: the signal generation, the transfer of the 
signal to the target organ, and the response to the transferred signal 
resulting in cardioprotection. The underlying mechanisms are complex 
and remain to date incompletely resolved [9,10].
Many previous studies have used surgical ligation of the femoral 
vessels with or without discontinuation of the femoral nerve [11] to 
induce preconditioning at remote sites. This invasive approach was 
further combined with mere visual control of ischemia and reperfusion 
success in the hindlimb without the benefit of objective and reliable 
quantitative measurement methods.
The unique potential of translating rIPC to the clinical setting de-
rives from its universal availability and non-invasive nature. A recent 
meta-analysis of current trials showed a clear effect of rIPC on clinical 
outcomes [12]. However, not all studies have concordantly reported ben-
eficial effects from rIPC, and some study populations did not show any 
infarct-sparing effects. Therefore, animal models remain the system of 
choice for molecular studies into the underlying signaling mechanisms in 
rIPC with particular importance for mouse models given the availability 
of knockout specimen. The ideal rIPC stimulus in animal models should 
mirror the maneuver in patients, thus avoiding the pitfalls of blood loss, 
inflammation and e.g., pain as induced by surgical techniques.
We have developed a clinically-relevant, non-invasive model of rIPC 
as translational bridge that closely mimics the approach in humans which 
avoids the caveats of previous approaches. We use a small occluder, 
which is placed around the right upper hindlimb, permitting a complete 
arrest of hindlimb perfusion. This occluder allows for an application of 
pressures after having been placed tightly around the hindlimb. Inflation 
will take place on the inner part of the occluder, while the shape and 
conformation of the outer part remain stable (see blood pressure cuffs 
in clinical routine). Importantly, this method avoids potential vascular 
and tissue damage while applying regulated pressure as required. In 
such studies, the efficacy of the ischemic episodes must be monitored to 
ensure reproducibility. We therefore established laser Doppler perfusion 
imaging (LDPI) measurements for the assessment of rIPC on hindlimb 
perfusion. This is a delicate issue as several circumstances influence the 
LDPI signal (e.g., the presence or absence of hair, the type of anesthesia, 
body temperature and position). We have therefore placed particular 
emphasis on the exact positioning of the laser beam and the depilatory 
measures as well as the placement/fixation of the mouse during LDPI 
measurements. Finally, combining LDPI with a manometer for pressure 
application allows for the determination of systolic blood pressures in 
mice in parallel to the rIPC maneuver.
Following the outline of our in vivo rIPC model we put a particular 
emphasis on the evaluation of a blood-borne protective factor released by 
rIPC to induce a cardioprotective signaling. In our protocol, we mainly 
rely on an open-chest I/R model, which we consider to be technically 
less challenging than other optional approaches including the so-called 
closed-chest models. However, the latter also represents an alternative 
to the proposed technique. We have provided a list including (dis-)
advantages of the different models in Table 1.
Studies in porcine models using heart transplants showed that rIPC 
remains effective in these denervated specimens. If rIPC released a 
protective substances distributed throughout the circulation then trans-
fer of blood or plasma from conditioned specimen to unconditioned 
recipients should recapitulate cardioprotection. We therefore present a 
novel method to assess how transfer of plasma especially from human 
conditioned donors to mouse models (e.g., with genetic deletion of 
target proteins) could be performed. This is a very effective method to 
assess the signaling in rIPC and to evaluate whether certain patients 
will benefit from rIPC while others do not.
Based on recent submissions, we here describe a modular approach 
to our protocols (Fig. 2). It consists of five modules: (1) A non-invasive 
preconditioning procedure for rIPC checked by LDPI technique to 
establish reproducibility [9,13]; (2) Open-chest myocardial I/R in vivo 
protocol complemented by a short outline of preconditioning of the 
index organ (IPC); (3) Assessment of cardiac function by ultrasound 
(US) or magnetic resonance imaging (MRI) approaches; (4) Post I/R 
tissue processing for monitoring infarct size by non-invasive late-gado-
linium enhanced (LGE) MRI or by staining the explanted and sectioned 
hearts with 2,3,5-triphenyltetrazolium chloride (TTC) and Evans blue 
dye; and (5) Plasma transfer experiments to assess the characteristics 
of the humoral factors released by rIPC to induce a protective cellular 
signal at a distance.
MATERIALS
Animals
Mice are kept at the local animal house in a temperature- and hu-
midity-controlled room under a 12 h light-dark cycle with free access 
to food and water. All experimental procedures described here were 
approved by the Landesamt für Natur und Umweltschutz, Reckling-
hausen, Nordrhein-Westfalen, Germany, and the Institutional Animal 
Care and Use Committee and conformed to the ‘Guide for the Care and 
Use of Laboratory Animals’ (NIH Publication 85–23, revised 1985).
NOTES: Experiments must comply with national and institu-
tional regulations concerning the use of animals for research 
purposes and permissions to carry out experiments have to 
be obtained.
HINTS: Generally, myocardial I/R injury as outlined here 
can be performed in all mouse models. In our laboratory, 
we use adult mice at a minimum of 12 ± 3 weeks of age and 
with an average minimum weight of 25 ± 4 g. Using younger 
or lighter animals may pose difficulties. This largely results 
from the technical difficulties in identifying the left and right 
coronary artery (LCA) in small specimen. Taking advantage of 
a wide variety of knockout models, we note that in genetically 
modified mice that affect vascular beds (e.g., eNOS-deficient 
mice [14]) the correct positioning of the coronary suture can 
be particularly delicate.
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Table 1. Advantages and disadvantages of available in vivo mouse infarction models.
In vivo model Advantages Disadvantages
Open chest technique • Robust experimental evidence/data, 
reproducibility
• Visual and ECG control of ligation 
success
• Surgery time of 20 min
• Requires mechanical ventilation
Permanent ligation • Less technically challenging • Lack of reperfusion (I/R injury not present)
• Large infarction
Closed-chest technique • Closed-conditions • Technically challenging
• Post-surgery defective healing
• Success of infarction only via ECG
Complete externalization of the 
heart technique
• Fast method (min)
• Omits mechanical ventilation
• Very short phase of global hypoxia during short phase of heart 
externalization (approx. 8 s)
• Requires advanced surgical skills and animal handling
• Difficulties in handling/detecting pneumothoraces
Figure 1. Schematic outline of several conditioning regimen. Myocardial I/R injury can be modulated by application of different ischemic conditioning 
approaches. Ischemic preconditioning and postconditioning relate to short non-deleterious phases of sublethal ischemia applied to the index organ (in this 
case the heart) before or after the main ischemia (row two and three). This can be conducted experimentally by arterial ligation and suture release in a 
repetitive manner and leads to reduction in infarct sizes. Remote ischemic conditioning is applied to a heart-distant organ, in this case the upper extremity 
through blood pressure cuff in- and deflations (row four). The stimulus can be applied prior to the heart (main) ischemia or—in case of perconditioning 
(row five)—during the main ischemia. Typically in all regimens 3–4 cylces of short non-deleterious conditioning ischemic events should be performed. 
This is typically 5 min long each. I/R: ischemia/reperfusion.
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Figure 2. Timeline of the modules performed during rIPC and IPC 
studies of the heart. While modules one and two (rIPC/IPC and myocardial 
I/R, respectively) are typically performed on day 0 with an approximate 
duration of 1.5 h, module three comprising different aspects of measuring 
cardiac function and tissue processing are performed at day 1 in our proto-
col. Transfer experiments can be performed at day 0 and are not included 
in the schema. Tissue processing can include any treatment necessary 
to evaluate the parameter of choice. However, we here focus on three 
aspects: infarct size, immunohistochemistry or imaging techniques US and 
MRI. rIPC: remote ischemic precondition; US: ultrasound: MRI: magnetic 
resonance spectroscopy.
Human materials
Our transfer experiments further included plasma from humans.
NOTES: Any study in humans requires approval by the in-
stitutional ethics committee and all participants must have 
given written consent to the study protocol in advance.
Reagents
 9 Acetic acid (Sigma-Aldrich, Seelze, Germany, cat. # 34255)
 9 Aquasonic Clear Ultrasound Gel (Parker Laboratories Inc, 
Fairfield, NJ, USA)
 9 Buprenorphine (Essex Pharma, München, Deutschland, cat. 
# PZN 0345928)
 9 CaCl2 (Sigma-Aldrich, Seelze, Germany, cat. # C1016)
 9 Carbogen (Air Liquide, Oberhausen, Germany)
 9 Evans blue (Sigma-Aldrich, Seelze, Germany, cat. # E2129)
 9 Glucose (Sigma-Aldrich, Seelze, Germany, cat. # G5767)
 9 Hair removing crème, Veet (Reckitt Benckiser Deutschland 
GmbH, Heidelberg, Germany)
 9 Heparin (70–100 IE; ratiopharm, Ulm, Germany)
 9 Isoflurane (Abbvie, Ludwigshafen, Germany, cat. # B506).
CAUTION: Prolonged exposure to isoflurane potentially causes 
central nervous system depression. An exhaust system to eliminate 
excessive isoflurane needs to be operational during the surgery.
 9 KCl (Sigma-Aldrich, Seelze, Germany, cat. # P9333)
 9 KH2PO4 (Sigma-Aldrich, Seelze, Germany, cat. # 1551139)
 9 MgSO4 (Sigma-Aldrich, Seelze, Germany, cat. # M7506)
 9 Mounting medium ‘Vitro Clud’ (R. Langenbrinck, Emmendin-
gen, Germany, cat. # 04-0001)
 9 Nair hair removal lotion (Church & Dwight Co., Inc, Ewing, 
NJ, USA)
 9 NaCl (Carl Roth, Karlsruhe, Germany, cat. # 3957.3)
 9 NaHCO3 (VWR, Darmstadt, Germany, cat. # 27.775.293)
 9 NaH2PO4 (Sigma-Aldrich, Seelze, Germany, cat. # 55011)
 9 Na2HPO4 (Carl Roth, Karlsruhe, Germany, cat. # T876.2)
 9 Octenisept (Schülke & Mayr, Norderstedt, Germany, cat. # 
173704)
 9 Omniscan gadolinium-based MRI contrast (Nycomed Amer-
sham, Oslo, Norway)
 9 Oxygen, medical (Linde, Unterschleissheim, Germany)
 9 Phosphate buffered saline without Ca2+/Mg2+ (Sigma-Aldrich, 
Seelze, Germany, cat. # D8537)
 9 Rompune (aniMedica, Senden-Bösensell, Germany)
 9 Sodium pyruvate (Sigma-Aldrich, Seelze, Germany, cat. # 
P8574)
 9 Ketamine (Pfizer, Berlin, Germany, cat. # NO1AXO3)
 9 2,3,5-triphenyltetrazolium chloride (Sigma-Aldrich, Seelze, 
Germany, cat. # 93140)
Recipes
TTC staining solution: Prepare two phosphate buffer solutions (buffer 
1 and buffer 2) by solving 14.2 g Na2HPO3 in 1 L ultrapure water (0.1 
M, buffer 1) and 6 g NaH2PO4 in 0.5 L ultrapure water (0.1 M, buffer 
2). Calculate 10 ml final TTC solution per heart. For this, add 7.44 ml 
of buffer 1 to 2.26 ml of buffer 2. Measure pH (target pH: 7.4). Add 
buffer 1 to decrease or buffer 2 to increase pH if incompliant with target 
value. Finally, add 100 mg of TTC to 10 ml of the mixture composed 
of buffer 1 and buffer 2.
CAUTION: This solution should be prepared freshly every day 
and stored in the dark.
Krebs-Henseleit buffer: The following procedure refers to a buffer 
volume of 2 L, which is to our experience sufficient for at least three to 
four isolated heart preparations. Final concentrations in 2 L buffer are 
given in brackets: Add in the following order 13.8 g NaCl (118 mM), 
0.7 g KCl (4.7 mM), 0.4 g MgSO4 (0.8 mM), 4.18 g NaHCO3 (25 mM), 
0.32 g KH2PO4 (1.2 mM), 1.8 g glucose (5 mM) and 0.44 g sodium 
pyruvate (1.1 mM) to 2 L of ultrapure water. When completely solved, 
gas buffer with carbogen. After a minimum of 15–20 min, add CaCl2 
(0.74 g; 2.5 mM final concentration) to gassed buffer. Filter buffer 
using a 0.45 µM filter.
CAUTION: This solution must be prepared freshly every day.
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Equipment
 9 Milli-Q Advantage A10, ultrapure water system (Merck Chem-
icals, Schwalbach, Germany
 9 Heated small animal operating table usually operated at 
37°C–38°C (Hugo Sachs Elektronik, March-Hugstetten, 
Germany, cat. # 50-1247)
 9 Mouse ventilator ‘Minivent’ (Hugo Sachs Elektronik, 
March-Hugstetten, Germany, cat. # 73-0044)
 9 Ventilation system (gases and isoflurane) (UNO Roestvaststaal 
BV, AA Zevenaar, Netherlands, cat. # 180000206, 180000002, 
180000004, 180000005, 180000010)
 9 Suspension device (Intubation Aid) (UNO Roestvaststaal BV, 
AA Zevenaar, Netherlands, cat. # 180000014)
 9 Occluder (OC4, OC 5, OC6, OC8) Kent Scientific, Con-
necticut, USA)
 9 Manometer (KAL 84, Halstrup Walcher, Kirchzarten, Germany, 
cat. # 9095.0074)
 9 Stereotactic microscope (Leica Mb 5; Leica MZG; Wetzlar, 
Germany)
 9 Camera (Hitachi HV C20AMP, Erkrath, Germany)
 9 Langendorff apparatus Basic IH-SR with aortic cannula and 
cannulation box (Hugo Sachs Elektronik, March-Hugstetten, 
Germany, cat. # 73-4343, 73-2806, 73-4019, 73-4021, 73-0129)
 9 Langendorff apparatus System Isoheart Software (Hugo Sachs 
Elektronik, March-Hugstetten, Germany, cat. # 73-4039)
 9 ClinScan 70/20 Superconducting Magnet System, including 
gradient system B-GA 12S2, MAGNETOM Avanto/Trio 
digital radio frequency system, syngo MR B17 acquisition 
software and animal holder (Bruker BioSpin MRI GmbH, 
Ettlingen, Germany)
 9 Mouse body quadrature volume radiofrequency coil (Bruker 
BioSpin MRI GmbH, Ettlingen, Germany)
 9 Model 1030 Monitoring & Gating System (Small Animal 
Instruments, Inc, Stony Brook, NY, USA)
 9 Vevo 2100 High Resolution Ultrasound System with MS400 
solid-state, linear array transducer and imaging station (FU-
JIFILM VisualSonics, Inc, Toronto, Ontario, Canada)
 9 Cooling plate (self-made)
 9 Pacemaker electrode (stimulator C type) (Hugo Sachs Elek-
tronik, March-Hugstetten, Germany, cat. # 73-3713, 73-0160)
 9 Infusion pump (Harvard Pump 11 Plus dual syringe, Harvard 
Apparatus, cat. # 70-4501)
 9 Polyethersulfone membrane filters 0.45 µm (Sartorius, Got-
tingen, Germany, cat. # 15406
 9 Laser Doppler perfusion imager (Perimed, PeriScan PIM 3, 
Software LDPIwin 3.1.2, Järfälla, Sweden)
 9 Thermomixer (VWR, Darmstadt, Germany, cat. # 460-0223)
 9 Infarction software Diskus (Hilgers, Königswinter, Germany)
 9 Wella Contura Professional Hair Trimmer (Wella, type HS60)
 9 Needle holder (Aesculap; Braun, Melsungen, Germany, cat. 
# FD233R)
 9 24G or 26G sterile needles (BD Microlance 3, BD Biosciences)
 9 21G venous cannulas (Braun, Melsungen, Germany)
 9 Syringes (sterile 1 ml; perfusor 20 ml; Braun, Melsungen, 
Germany)
 9 4-0, 5-0, 6-0 prolene suture (Ethicon; Johnson & Johnson, 
Norderstedt, Germany, cat. # EH 7814, EH 7231, EH 7478)
 9 Small and micro-scissors (FST, Essen, Germany, cat. # 14059-
11, 15007-08, 14064-11)
 9 Forceps (FST, Essen, Germany, cat. # 11203-25, 11069-08, 
11616-15, 11506-12, 11051-10; Aesculap Braun, Melsungen, 
Germany, cat. # BN731R, BD 311R)
 9 Retraction Kit (FST, Essen, Germany, cat. # 18200-20)
 9 Small silicon tube (Reichelt Chemietechnik, Heidelberg, 
Germany)
 9 Gauze pads (Hartmann, Heidenheim, Germany, cat. # 407835)
 9 Glass slides (Carl Roth, Karlsruhe, Germany, cat. # K532.1)
 9 Centrisart tube (Sartorius, Göttingen, Germany, cat. # 13249)
 9 Neonatal MR-compatible electrocardiogram (ECG) electrodes 
(Vermed, Bellows Falls, VT, USA)
PROCEDURE
Induction of anesthesia, intubation, mechanical ventilation • TIMING 10–12 min
HINTS: For all modules, mice are under deep sedation over the whole specific procedures. We use tracheal intuba-
tion rather than tracheotomy as outlined in other protocols [15]. In our hands this provides a much better handling 
of mice in the wake-up period.
1. The mice are kept at the local animal house and will be transferred to the operation room on the day of surgery.
CRITICAL STEP: New mice shipped from suppliers should be allowed to become accustomed to the environment 
(approximately seven days). Check mice for wounds, healing defects, and infections, as an activation of the immune 
system can significantly influence I/R outcomes.
2. Set-up the surgical heating plate, ventilation system (gases and isoflurane), anesthetics and materials.
3. Record the following: mouse weight, age, strain, date and time of experiments. Complete one surgery pro-
tocol sheet per mouse.
4. Calculate the necessary dose for ketamine and rompune required for deep anesthesia and buprenorphine for 
analgesia (ketamine 100 mg/kg body weight, rompune 10 mg/kg, buprenorphine 0.05–1 mg/kg body weight).
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NOTES: Drugs used for sedation and analgesia as well as animal handling procedures must comply with national 
and regional laws and will require permission from the necessary committee. Anesthesia depth was confirmed by 
failure of limb withdrawal upon toe pinching. (Order of anesthesia induction, see supplementary Fig. S1)
5. Fill a 1 ml sterile syringe with the calculated amount of anesthetics. Inject the drugs carefully intraperitone-
ally (i.p.) using a 24G or 26G sterile needle. Wait for the cessation of any spontaneous movement (duration 
8–10 min), spontaneous breathing will persist.
6. Remove the chest hair by using a small animal shaving machine. This should take place with distance to the 
surgical site to avoid infections. Hindlimb hair removal is also mandatory for LDPI studies.
7. Attach the mouse with the front teeth to the suspension device (Fig. 3A) and position cold light in front of 
the trachea.
HINTS: Use small forceps to retract tongue out of the oral cavity to one side of the mouth, locate the illuminated 
area within the trachea and use a small tube to conduct intubation (21G venous cannulas represent excellent tubes 
for mouse intubation, Fig. 3B). Detach the mouse carefully from the suspension device, place it onto the surgical 
plate and attach the tube to the ventilation system. Intubation success can be visualized when the chest and not 
the abdomen moves with mechanical breathing. In some respirators, barometers may also indicate correct tube 
positioning by measuring spontaneous breathing. We set our respirators to a breathings frequency of 140/min and 
a tidal volume of 100–120 µl. Please refer to the manufacturer’s instruction for correct settings as this relies on the 
respirator’s specifications and the tubing.
8. Maintain anesthesia using isoflurane (1.2–2 Vol%) in conjunction with a gas mixture of 0.2 L/min O2 and 
0.2 L/min compressed air. Fix the tube and the extremities using adhesive tape. For help in case of difficult 
intubation see troubleshooting.
Figure 3. Intubation procedure. A. Use a suspension device and suspend the mice with the upper front teeth. B. Cold light is very helpful when identi-
fying the larynx. Place light against the middle of the trachea and pull the tongue out (upper panel). The asterisk marks the larynx in bright light. One-way 
sterile venous cannulas are optimal tracheal tubes for mice. Lower panel shows intubation procedure.
rIPC on the hindlimb • TIMING 45–50 min
NOTES: rIPC originates a signal in the remote organ that is readily transferred to the target organs. The remote 
site can be a solid organ, a specific vascular bed or an extremity. For clinical translation, leg or arm rIPC are cer-
tainly the most favorable approaches. Inflation of a small occluder device—in analogous to blood pressure cuffs 
in patients—is a simple approach to activate protective signaling. If an exclusion of the afferent nervous system is 
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part of the experimental approach, excision of the femoral nerve prior to rIPC can be an advantageous approach.
9. Sufficient anesthesia is achieved when the withdrawal reflex of the hindlimb vanishes.
10. Deflate the occluder completely (Fig. 4A) and place it around the upper hindlimb (Fig. 4B). Be prepared by 
having different sizes of occluders available to ensure complete cessation of perfusion.
11. Attach the occluder via a tube to the manometer (Fig. 4C) and zero the system by opening it to room air.
NOTES: LDPI is a non-invasive technique to study the cessation and recovery of perfusion during occluder in- and 
deflation periods. Incomplete blood flow arrest in the rIPC ischemic phases may indicate e.g., that the occluder size 
is too large in relation to the respective hindlimb dimensions (e.g., hindlimbs in obese mice vs. standard littermates). 
Careful attention should be paid to the LDPI set-up and surrounding environmental conditions (see troubleshooting). 
Avoid changes in light intensity and quality during LDPI studies, adjust to the basal background threshold and do 
not modify hereafter. Keep and mark (if not conducted by the system’s software) the distance between leg and laser 
source (approximately 20 cm). Maintain heating plate temperature at 37°C–38°C throughout. Do not move the 
mouse. This again requires a sufficient depth of anesthesia. Troubleshooting for LDPI measurements is provided 
in the TROUBLESHOOTING section.
12. Re-fix the hindlimb carrying the occluder using adhesive tape. Position the LDPI to a region below the oc-
cluding device (e.g., distal lower leg) with a small region of interest (Fig. 4D).
13. Begin with the recording of the LDPI measurements using the scanner in the Duplex mode at a sampling rate 
of 100 Hz, filter cut off frequency 1.25 Hz, and a threshold for light intensity of 0.3.
14. Start the rIPC protocol by inflation of the occluder. This will increase the inner diameter and causes an arrest of 
blood flow to the hindlimb. Typically, a pressure of 200–250 mmHg will be sufficient. If higher pressure must be 
applied, consider decreasing the diameter of the occluder. Likewise, if perfusion ceases below 120–150 mmHg, 
a larger occluding device may be helpful. After the ischemic phase of the rIPC stimulus (5 min) release the cuff 
pressure. This should result in a recovery of blood flow. Observe the pressure levels at which perfusion restarts. 
This is the systolic blood pressure and should be noted as such. Within the first 1–2 min, an increase of flow 
above baseline levels can be noted. This indicates hyperemic flow in the reperfusion phase (Fig. 4E) [9]. Due 
to its non-invasive nature, LDPI is by itself a semi-quantitative method. In this protocol, we take advantage 
of LDPI to measure baseline hindlimb perfusion, check whether cuff-inflation causes a complete cessation 
of blood flow and finally test whether reperfusion is achieved when releasing the pressure from the cuff. 
Units in the graph are therefore arbitrary units. We expect an increase of blood flow to 150%–220% of the 
baseline perfusion. Comparable values were obtained for humans [9].
15. Continue with the next phases of the rIPC protocol, e.g., a total of 4 phases with 5 min of hindlimb isch-
emia and 5 min of reperfusion. This totals 40 min. Bear in mind that directly after the rIPC maneuver, many 
researches wish to continue with the main myocardial ischemia. Depending on the exact protocol, plan on 
immediately starting with surgery once the protocol is finished. Help from a second person in order to remove 
the LDPI/rIPC devices while the other person prepares for surgery may be helpful.
Myocardial I/R including IPC • TIMING 45–90 min with or without IPC protocol
NOTES: The open-chest myocardial I/R model exhibits certain advantages and disadvantages. It is certainly the 
most common in vivo I/R model and results (infarct sizes, arrhythmia, and cardiac enzyme levels) can be related 
to a vast amount of prior studies. However, extrapolating results from mouse to the clinical situation is difficult as 
the pathomechanism of infarction in patients is the spontaneous plaque rupture. Other in vivo infarction models 
include the permanent ligation technique, the closed-chest model [16], and an open-chest model with complete 
translocation of the heart outside the thorax [17].
While parts 9–15 of the protocol focus on rIPC, IPC is outlined in conjunction with the following sections on 
myocardial I/R because it involves the opening of the thorax.
16. Use antiseptics to minimize bacterial flora in the operation field. Wait for skin disinfectant to dry. The next 
steps should be conducted under a dissection microscope.
17. Perform skin incision using small surgical scissors. Cut from the middle of the sternum over the heart (heart 
beat can be localized by palpation prior to surgery) towards the left axilla. The total length of the incision 
should be 15–18 mm.
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18. Use appropriate tweezers for a blunt preparation of the two muscle layers (intercostal) and two surgical 
hooks until ribs can be visualized.
19. Opening of the thorax will be performed between the third and fourth rib. Use micro-scissors for this part. 
Prepare the two intercostal muscle layers. Two surgical hooks placed at either side of the incision are used to 
increase the diameter of the thoracotomy (Fig. 5A). Gentle force on the hooks can be helpful to gain access 
to the pericardium (Fig. 5B).
20. Resect the pericardium above the heart. This avoids post-surgery pericardial effusion.
HINTS: Localize the LCA (Fig. 5C and 5D). Use a 6-0 prolene suture to encircle the artery halfway from base to 
apex with a loop.
21. At this point of the protocol, continue either with IPC followed by main ischemia or go directly to Myocar-
dial I/R.
21.1. IPC
21.1.1. Pass the suture through a small silicon tube. Attach the endings of the suture to a magnetic 
holder at either side of the mouse.
21.1.2. Begin with IPC protocol by moving the magnetic holders simultaneously to the left and to the 
right away from the mouse, which will tighten the suture and occlude the coronary artery (Fig. 
6A-6C).
21.1.3. Observe whether the myocardium turns grey below the occluded artery.
21.1.4. After this ischemic phase, release the suture by moving the magnetic holders towards the mouse 
and observe whether the myocardium returns to its red color.
21.1.5. Finish the IPC protocol by conducting e.g., a total of 4 cycles with 5 min of ischemia and 5 min 
of reperfusion per phase. Then continue with option B to perform the myocardial I/R.
21.2. Myocardial I/R
NOTES: Mouse coronary arteries largely consist of two main arteries (left and right coronary artery). A clear 
separation into a circumflex artery and left anterior descendent (LAD) as compared to humans does not exist [18]. 
The ligation of a left wall myocardial territory therefore refers to occlusion of the LCA and not the LAD as noted 
in many previous publications.
21.2.1. Position a small silicon tubing above the loop (Fig. 6D) and place a tight knot above the tube. 
This way of occluding the LCA remain tightened for a long time period but cannot be released 
as quickly as required for IPC regimens.
21.2.2. Observe whether the myocardium turns grey distal to the knot.
21.2.3. Release the surgical hooks slightly. Place a wet gauze pad on the operation site to avoid drying up.
21.2.4. Continue ischemia for the desired time, e.g., 30 min as frequently applied by our laboratory.
21.2.5. Carefully observe the animal and the operation site for any immediate signs of acute heart failure 
(arrhythmia, drop in heart rate). Any of these signs should result in an immediate cessation of 
the procedure.
22. At the end of the IPC protocol followed by main ischemia (both IPC and Myocardial I/R) or option Myo-
cardial I/R (main ischemia only) release the silicon tube to induce reperfusion. Observe the return of a 
more reddish color to the myocardium. Loosen the suture which will be left in place and retightened in the 
post-processing protocol.
23. Close the thorax cavity layer by layer using a 4-0 prolene suture. Begin with the ribs and re-approximate 
the ribs using a silk suture. Slightly increase tidal volume on your respirator (volume controlled respirator 
as performed by us) or increase inspiratory pressure (pressure controlled ventilation) depending on your 
respirator’s specifications. This leads to a fully inflation of the lung. Then tighten knots between the ribs, 
adapt muscle layers (2-3 5-0 prolene sutures) and perform skin closure (4-5 5-0 prolene sutures).
24. Switch off the isoflurane line. After 2–3 min, observe whether the mouse regains consciousness and starts 
spontaneous breathing. Once spontaneous breathing is sufficient, extubate the mouse. Place the animal in a 
clean and warm cage and inject 0.05–1 mg/kg buprenorphine subcutaneously for analgesia every 8 h.
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Figure 4. Remote ischemic preconditioning using a non-invasive occluder-based LDPI controlled approach. A. Set of occluders at different sizes 
(left 8 mm inner diameter, right 5 mm). B. The occluder is placed around the hindlimb of a C57BL/6 mouse, which is fixed with adhesives on a surgical 
heating plate. Procedure can be compared to placement of blood pressure cuffs in humans, as used in conditioning studies. C. The cuff tubing is the 
attached to the manometer, which can precisely measure and apply pressure to inflate the cuffs inner diameter. The laser Doppler is placed above the 
mouse and the laser beam place on the lower hindlimb. D. Picture shows LDPI on a NMRI mouse. Hair was carefully removed on the lower legs to allow 
full laser penetration. E. Typical LDPI recording with 3 phases: baseline perfusion (1); arrest of perfusion when inflation the cuff to 200 mmHg or above 
(2) and reperfusion phase (3). Notice the increase in reperfusion above baseline levels, which is an indication of hyperemia in reperfusion. Off note, 
reperfusion as measure by LDPI has its onset at the systolic blood pressure. Careful examination of perfusion in relation to pressure on the manometer 
could additionally supply these pressures in the individual mouse. rIPC: remote ischemic reconditioning; LDPI: laser Doppler perfusion imaging; NMRI: 
Naval medical research institute.
PAUSE POINT
Non-invasive measurement of cardiac function by US or MRI • TIMING 15–60 min
NOTES: Non-invasive determinations of left ventricular ejection fraction (LVEF) are best calculated from accurate 
measurements of LV end-systolic volume (LVESV) and LV end-diastolic volume (LVEDV). The two most common 
imaging platforms used for making these measurements in mice are high-frequency US and high-field MRI. Each 
modality has its pros and cons, so the best choice is largely determined by the instrumentation, expertise and staff 
support available at a particular institution. Conventional clinical approaches to echocardiography typically use a 
limited number of long- and short-axis image planes to make rough estimates of LV volumes. However, the accu-
racy of the LV volumetric determinations made by US can be improved to rival that of MRI by adopting the MRI 
convention of analyzing 6–8 contiguous, 1mm-thick, short-axis image slices capturing the entire LV from base to 
apex. This typically involves immobilizing the transducer and using a micromanipulator to translate the stage (or 
transducer) in precise 1mm increments along the long-axis of the LV. Going beyond the global measure of EF, both 
US and MRI can be used to determine regional cardiac function through the measurement of myocardial strain via 
speckle-tracking and DENSE, respectively [19].
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25. Cardiac imaging is typically performed 24 or 48 h post-reperfusion, allowing the mouse adequate time to 
recover from infarction, and yet imaging prior to the onset of significant LV remodeling. The animal is lightly 
anesthetized with isoflurane (as described above) and placed on a warm surface during preparation for imaging.
25.1. For US imaging, this involves shaving the chest region over the heart with a hair trimmer, then applying 
Nair for the minimum amount of time necessary to remove any remaining hair from the region to be 
imaged. Particular care should be taken to rinse the area treated with Nair thoroughly to prevent burns 
from the active ingredient (sodium hydroxide). Care must also be taken to remove any air bubbles 
from the US gel (by centrifugation, if necessary) to avoid the image artefacts that inevitably result 
from imperfect acoustic coupling by the US gel.
25.2. For MRI, the same combination of trimming and Nair treatment is used to remove all hair from 2-3 
fore- and hindlimbs for the placement of neonatal ECG electrodes. The self-stick, MR-compatible 
ECG electrodes are then applied to the limbs to achieve maximal surface contact and secured with 
adhesive tape.
25.3. Once prepared, mice are transferred from the prep area to the imaging platform, whether it be a heat-
ed stage with integrated ECG electrodes (for US) or a radiofrequency (RF) coil to be positioned at 
the isocenter of the MRI scanner. Regardless of imaging modality, particular care must be taken to 
actively monitor and maintain core body temperature at 37°C ± 0.5°C since both since both heart rate 
and cardiac function are dependent on temperature
25.4. Under light isoflurane anesthesia (1.2%–1.5% in medical oxygen), with a core body temperature of 
37°C ± 0.5°C and a heart rate of 475–575 bpm, non-invasive imaging is then performed to capture 
1mm-thick, short-axis images of the cardiac cycle at 1mm increments from base to apex according to 
manufacturer’s instructions. Supplementary instructions are available on the manufacturer’s websites.
25.5. If high-resolution maps of regional contractile function are desired, then additional imaging time may 
be needed to acquire US images at high temporal resolution (50–200 frames/cardiac cycle) or, in the 
case of MRI, by acquiring additional DENSE [19] or HARP [20] data to track myocardial motion 
over the cardiac cycle.
25.6. Images are typically stored in DICOM format for the analysis of LVESV, LVEDV and LVEF using 
post-processing software provided by the respective vendor. For MR image datasets, alternative methods 
of image analysis include free online resources such as Segment (http://medviso.com/products/segment).
Tissue processing to assess infarct size after rIPC/IPC • TIMING 2.5 h
26. After Step 25, an intraperitoneal catheter of PE10 tubing is typically positioned in the mouse prior to inser-
tion into the RF coil. The PE10 tubing is then routed out of the bore of the MRI scanner and connected to an 
insulin syringe so that Gd-based contrast agent (Omniscan) can be infused when needed as a bolus dose of 
0.5 mmol/kg. LGE imaging is initiated 15–20 min later using either a cine-FLASH acquisition at an elevated 
flip angle [21] or an inversion recovery pulse sequence [22].
26.1. By MRI. In the event that MRI is used to determine cardiac function (Step 25), investigators have the 
option of non-invasively determining the size and location of myocardial infarction using LGE MRI 
[21]. Alternatively, myocardial injury can be measured from circulating levels of cardiac enzymes 
(particularly troponin). In this context, recent studies in small rodents have showed that troponin levels 
peak at 24 h in rats while the maximum in mice can be detected 24–48 h after the onset of ischemia 
[23]. In case, troponin blood levels are considered, attention should there be paid to the exact timing 
of blood sampling for comparison. Alternatively, troponin level follow-up studies at consecutive time-
points (e.g., every 6–12 h) can be performed thus providing an area under curve result.
26.2. By TTC staining. For determination of infarct sizes (lethal I/R injury), allow a reperfusion period of 
24 h. However, reperfusion may be shorter or longer depending on the respective scientific question.
27. Apply narcotics to the mouse (Steps 4 and 5), but add 70–100 IE unfractionated heparin per kg bodyweight 
as i.p. bolus to establish complete anticoagulation. Wait for deep anesthesia.
28. Fix the mouse on the surgery plate and quickly perform the sternotomy. Excise the heart within 30 s and 
transfer it to the cooling plate filled with 4°C ice-cold sodium chloride (NaCl) 0.9% or a buffer of choice 
(Fig. 7A). The heart will immediately stop beating. The use of Ca2+ free buffers may further help.
29. Prepare the heart for aortic cannulation.
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CAUTION: The following preparation of the heart must be conducted meticulously to preserve the integrity of the 
heart and the aorta, but should be completed as soon as possible with a maximum duration of 3–4 min. A thorough 
knowledge of the mammalian heart anatomy is required. Begin by dissecting the lungs (if obtained from the thorax 
en block) and thymus. Continue with the adipose tissue surrounding the large vessels. Localize the aorta, of which 
a remainder of 4–5 mm in length should be left for cannulation. Transfer heart to cannulation box.
HINTS: Using two forceps, take hold of the aorta, pull over the metal cannula and fix using a silk suture (Fig. 7B). 
The cannula must end distal to the aortic valve (Fig. 7C). Avoid any air in the cannula, aorta and left ventricle.
30. Attach the cannula with the isolated heart to a syringe filled with NaCl 0.9%. Gently perfuse the heart free 
of blood.
31. Re-occlude the LCA using a 6-0 suture. Alternatively, the investigator may wish to leave the original suture 
in place after myocardial in vivo I/R. This is then re-occluded. Both are practical alternatives.
32. Attach the cannula to the syringe filled with 1% Evans blue and flush the heart gently with dye. Alternatively, 
staining with 5% Evans blue can be performed if 1% does not provide sufficient results. Furthermore, in vivo 
perfusion with dye is an alternative to the proposed procedure.
33. Detach the heart from the cannula and wrap in cling film. Transfer the heart to the –20°C freezer and let the 
heart freeze (duration 60 min).
34. Unwrap the heart and cut it into 2 mm slices while holding it with forceps. For cutting, razor blades or mi-
crotome blades should be used.
35. Transfer the slices to a vial containing preheated TTC (37°C). Incubate for 5 min at 37°C on a shaker.
36. Obtain photos of the slices and label the photos (order of slices). Then use a precision scale and record the 
weight of each slide.
37. Use an infarction software to determine the size of the left ventricle, AAR (area of the left ventricle not 
stained by Evans blue) and infarct area (white as determined by TTC). Use software algorithm to assess the 
AAR/left ventricle (quality control) and infarct size per AAR based on planimetry in all slices. (Refer to 
ANTICIPATED RESULTS section for typical results, e.g., with or without rIPC or IPC treatment).
Figure 5. In vivo LCA ligation for the induction of I/R. A. The thorax is opened (incision length 15–18 mm). The wound is held open by surgical 
hooks. Access to the heart is gained between third and fourth rib. B. The intercostal muscles are carefully prepared to gain access to the pericardium. C. 
After identification of the LCA, place the suture for IPC or myocardial I/R in a loop around LCA. D. Note that the LCA will appear white (scattered lines) 
while cardiac veins have a much thinner vessel walls and typically appear filled with blood. IPC: ischemic preconditioning; LCA: left coronary artery; I/R: 
ischemia/reperfusion.
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Transfer plasma preparation from donors e.g., humans • TIMING 60–80 min
NOTES: This is naturally an ex vivo experiment with certain disadvantages, e.g., the lack of whole blood prepa-
rations and an intact circulation. However, it is an elegant bio-assay to test a distinct signaling elicted by rIPC.
HINTS: Isolated mouse hearts can be perfused with ultrafiltrated transfer plasma in a retrograde perfusion system 
according to langendorff [9,24-26] to test whether protective substances in the donor plasma are effective in the 
recipient heart. Transfusion of biological fluids and in particular plasma to isolated mouse hearts operated in a lan-
gendorff mode is difficult to achieve [27] particularly when involving interspecies samples (human to mice). The 
transfusion of complete plasma/serum or whole blood preparations can potentially initiate deleterious immunogenic 
responses and result in vascular obstruction in the recipient heart and immediate heart failure. Therefore coronary 
flow (perfusate flow) should be monitored continuously while any significant changes in perfusion can indicate 
heart failure. Furthermore pacing must be continued throughout. Failure of pacing may also be an indicator for 
heart failure. Cut off filters can be used to obtain a filtrate without proteins that are larger than 10–20 kDa while 
the size of protective factors is expected to be smaller than this. The dilution of this transfer plasma followed by 
a co-infusion with the perfusion puffer through the side arm of a langendorff system is one applicable option for 
transfer experiments.
38. Obtain the required blood (in our study human blood was used) [9], anticoagulated with heparin [28]. Cen-
trifugate at 800 × g for 10 min (4°C), this avoids hemolysis.
39. Separate plasma from the blood cell compartment.
40. Add 2.5 ml of plasma to a centrifugal ultrafiltration unit (NMWCO 20kDa) and then insert the floater. Let 
tube with inserted floater sit for 5 min to allow filter to be completely wet.
41. Centrifugate at 2000–2500 × g for 35–40 min (4°C). Quickly obtain the filtrate (approximately 500 µl from 
2.5 ml starting volume) from the floater and transfer it to clean tubes on ice.
42. Incubate equal amounts of filtrate (transfer plasma) and Krebs-Henseleit buffer (see MATERIAL) to prepare 
a stock solution for heart perfusion.
Figure 6. Schematic drawing of coronary ligation set-up for IPC and ischemia. Pass suture through tube, then encircle LCA. Pass the suture again 
through the tube. A. Arrows indicate direction of force to ligate LCA in the ischemic phases of the IPC protocol. B. Pulling the suture ends way from the 
mouse leads to closure of the LCA. C. Photograph showing magnetic holders to which the suture is attached during IPC. D. In contrast to IPC, during 
myocardial main I/R, a silicon tube is placed on the loop that encircles the LCA. Place a tight surgical knot on the silicon tube to ligate the LCA. IPC: 
ischemic preconditioning; LCA: left coronary artery.
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Figure 7. Excision of the heart. A. Cooling plate filled with ice cold NaCl 0.9%, which is used for preparation of the heart for cannulation. B. Cannula-
tion chamber with metal cannula and preformed suture loop. C. Aorta is cannulated and suture closed to hold heart in place. Asterisk indicates the end 
of the aorta and the suspected area of the aortic valve and RAA indicates right atrial appendage. D. Attach cannulated heart to the langendorff system.
Transfer experiments using cross-species transfer of donor plasma (e.g., human plasma) to isolated recipient 
mouse hearts in a langendorff apparatus • TIMING 102–105 min
43. Have Krebs-Henseleit solution (see MATERIAL) at hand, which should be prepared daily.
44. Turn on water baths, heat to 39°C (final temperature in perfusion chamber will be approximately 37°C due 
to heat loss via tubing).
45. Gas Krebs-Henseleit with carbogen (95%O2, 5%CO2) for 15 min to obtain a pH of 7.4 in the perfusate. Have 
Krebs-Henseleit cycle through the apparatus and ensure that perfusion chamber is filled with perfusate.
46. Set up a precise medical perfusor. From the perfusor, a line will run to the side arm of the perfusion chamber. 
Fill this solution in the perfusor syringe and attach it to the langendorff apparatus. This way, liquids such as 
transfer plasma can be co-infused to the isolated hearts.
47. Go ahead with Steps 27–30. Attach the cannulated heart to the langendorff apparatus (Fig. 7D).
48. During this procedure, the perfusor should be in running mode.
49. Set perfusion pressure to 80–100 mmHg (constant pressure mode).
50. Attach pacemaker electrode and stimulate the heart at a constant rate of 600 bpm.
51. Start the recording software to record at the minimum, aortic pressure and coronary flow.
52. Allow equilibration of the heart (20 min). The net coronary flow will hereafter equilibrate to 2.5–3.5 ml/min. 
Maintenance of an adequate temperature (37°C–38°C is required. If possible the chamber temperature should 
therefore be monitored.
53. Start the co-infusion of transfer plasma by infusing 1 ml/min when coronary equilibrium flow is 2.5 ml/min. 
Adapt the flow by increasing perfusor speed accordingly to maintain this relation. Continue for 20 min.
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CRTICAL STEP: This requires a higher amount of blood and resulting transfer plasma and should be considered 
when planning the experiment. Off note, when investigating the contribution of the NO system to conditioning 
[9,11,29,30], all handling materials and liquids must be tested for respective nitrite contaminations using highly 
sensitive techniques [31].
54. Switch off the perfusion line including transfer plasma perfusor to establish global ischemia. Continue global 
ischemia for 30 min.
55. Reperfuse the heart for 60 min, and then detach the heart from the cannula and process as required.
Table 2. Troubleshooting.
Step Problems Causes Suggestions
5,7 Sedation depth insufficient Insufficient drug concen-
tration for the individual
Have the mouse breath isoflurane through mask until depth of narcosis is sufficient.
7 Intubation failure Difficulties locating 
larynx
Place cold light strictly in front of the larynx, perform second attempt or have a 
second operator perform intubation.
If mouse is without ventilation and spontaneous breath for more than 1 min, consid-
er killing the mouse.
7 Ventilation failure Rupture of the lung, 
tension pneumothorax
Kill the mouse, check ventilation system, e.g., using an artificial lung, decrease tidal 
volume and ventilation pressures.
18–20 Bleeding into pericardium Surgical manipulation on 
fragile structures
Kill the mouse.
20 Difficulties locating coronary 
artery
The coronary anatomy 
varies in strains
Gently push the heart out from the thorax by pushing against the right sight of the 
thorax. Slightly increase thoracotomy length to the right sight while avoiding pneu-
mothoraces. In some strains, e.g., lacking endothelial NO synthase, visual location 
of the coronary artery is particularly difficult. In these cases, the typical location of 
the coronary could be assumed and the ligation performed. Ligation success will be 
obtained after staining for AAR and infarction-to-risk area.
28,31 Large remaining amount of 
blood in the excised heart
Insufficient anticoagu-
lation
Add heparin (e.g., 5000–10000 IE per 10 ml preparation buffer) to the buffer in the 
cooling plate.
31 Difficulties in aortic cannu-
lation
Short aorta Aorta should be at a sufficient length. Do no resect below the aortic valve.
31 Leakage from the cannulat-
ed aorta
Insufficient ligation Apply a second ligation quickly. Bear in mind that the total preparation time should 
stay limited to avoid further global hypoxia/ischemia. Omit the heart if leakage 
cannot be located.
32 Coronary ligation cannot be 
re-located
Specific anatomical 
characteristics in particu-
lar mouse strain
Leave the primary suture unligated in the thorax during in vivo reperfusion period. 
After heart excision re-ligates this suture.
52 Arrhythmia Incorrect composition of 
perfusion buffer or long 
heart preparation time
Check pacemaker set-up and buffer composition. Keep track of your preparation 
time (until cannulation). Try to further minimize preparation time.
ANTICIPATED RESULTS
Following our protocol, we believe that investigators will be able to 
independently perform mouse intubation and anesthesia. Researchers 
will be able to reproducibly apply conditioning techniques and conduct 
infarction studies themselves. While the aspect of myocardial I/R natu-
rally applies particularly to investigators in the field of cardiovascular 
research, conditioning and particularly rIPC can be used by many re-
searches in different fields, e.g., acute medical care, neurology (rIPC in 
the setting of stroke [32]), nephrology or hepatology (kidney and liver 
transplantation as clinically relevant models of organ I/R). Arguably, 
this is a model for use in mice lacking many aspects of cardiovascular 
patients. However, it is presumably the best approach to detect novel 
signaling components of myocardial I/R injury warranted to reduce 
mortality in patients. At all steps of the concurrent protocol we have 
put particular emphasis on the standardization and reproducibility. This 
pertains to our simplified conditioning technique as well as myocardial 
I/R injury, MRI and finally the analysis of tissues.
Infarct sizes
Complete I/R injury will be best analyzed after 24 h by TTC (ex-
emplary micrographs in Fig. S2 and for imaging in Fig. S3). Less 
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reperfusion will result in small infarct-to-risk sizes. Longer reperfusion 
will cause remodeling to an extend that a final scar is formed. Our in 
vivo I/R (30 min ischemia, 24 h reperfusion) model typically produces 
a medium infarct size of approximately 35% (infarct per AAR) with a 
standard deviation of 4%–5% as determined by TTC staining. Slight yet 
insignificant differences may occur between investigators. We therefore 
advice that one investigator should perform at least the critical coronary 
ligation step per study.
Ischemic conditioning
Ischemic conditioning techniques are probably the best available 
cardioprotective methods. rIPC reduces infarction-to-risk by approxi-
mately 50% in both C57BL/6 and NMRI wild-type mice [9]. The latter 
have slightly thicker legs. Application of an IPC regimen (4 × 5 min 
coronary occlusion followed by 5 min of reperfusion) produces an even 
more pronounced decrease in infarction size. AAR as determinant of 
reproducibility did not differ. Based on an additional study in mice, 
we achieved a mean infarct size of 36% ± 5% (mean ± SD) of the area 
risk with a reduction in I/R injury to 18% ± 6% after the described 
rIPC maneuver.
Taking together, the infarction model has been applied in a wide va-
riety of studies and has proven excellent reproducibility [9,16,24,33,34]. 
The conditioning techniques represent a simple yet highly effective tool 
to reduce lethal myocardial I/R injury. In combination, this bioapproach 
is a valuable animal model for translational research in the scope of 
myocardial infarction and cardioprotection.
Table 3. Troubleshooting LDPI.
Problem Possible reason Solution
Poor LDPI signal quality Insufficient skin area for adequate 
measurements
• Gently remove hindlimb hair, e.g., by using depilatory creme
• Avoid shaving as excessive mechanical manipulation can significantly alter 
skin perfusion
Changing LDPI signal Changes in light conditions • Try to maintain the same light conditions throughout the experiments and 
adjust the threshold to the background light conditions
• Maintain distance of the detector to the hindlimb at the exact same position 
(typically 20 cm)
Changing LDPI signal Poor tissue perfusion due to 
changes in ambient temperature
• Maintain the exact same temperature throughout the experiment particularly 
avoiding cooling draughts
• A closed room for experiments has been proven to be superior for LDPI 
experimental outcomes
No recovery of perfusion signal • Cuff too small
• Hindlimb has moved
• Change to larger cuffs
• Fix hindlimb properly
TROUBLESHOOTING
Table 1 lists potential (dis-)advantages of the different in vivo 
models. Troubleshooting advice can be found in Table 2 and Table 3.
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